Season 10 · Episode 27
S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
OncLive® On Air · OncLive® On Air
April 22, 20249m 29s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.